Exploration of Pro-oxidant and Antioxidant Activities of the Flavonoid Myricetin
Overview
Biology
Endocrinology
Authors
Affiliations
Objectives: Flavonoids are ubiquitous phenolic plant metabolites. Many of them are well known for their pro- and antioxidant properties. Myricetin has been reported to be either a potent antioxidant or a pro-oxidant depending on the conditions. The reaction conditions for the pro- and antioxidant activities were therefore investigated using variations of the deoxyribose degradation assay systems.
Methods: The deoxyribose degradation assay systems were conducted as follows; H(2)O(2)/Fe(III)/ascorbic acid, H(2)O(2)/Fe(III), Fe(III)/ascorbic acid, and Fe(III). Each system was carried out in two variants, FeCl(3) (iron ions added as FeCl(3)) and FeEDTA (iron added in complex with ethylenediaminetetraacetic acid).
Results: When ascorbic acid was present, myricetin showed antioxidant properties, especially when it occurred in complex with iron. In ascorbic acid-free systems, pro-oxidant activities prevailed, which where enhanced if iron was in complex with EDTA.
Discussion: Myricetin's antioxidant activity depends on both the reactive oxygen species (ROS) scavenging and iron ions chelation properties. The pro-oxidative properties are caused by reduction of molecular oxygen to ROS and iron(III) to iron(II). Myricetin is able to substitute for ascorbic acid albeit less efficiently.
Yestemirova G, Yessimsiitova Z, Danilenko M Pharmaceuticals (Basel). 2024; 17(5).
PMID: 38794189 PMC: 11124333. DOI: 10.3390/ph17050619.
Yifan X, Jingfeng H, Huichuan Z, Junqian L, Zhenzhou J, Lixin S Toxicol Res (Camb). 2024; 13(3):tfae073.
PMID: 38765240 PMC: 11100354. DOI: 10.1093/toxres/tfae073.
Grabarczyk M, Ksiazek-Winiarek D, Glabinski A, Szpakowski P Pharmaceutics. 2023; 15(9).
PMID: 37765263 PMC: 10537369. DOI: 10.3390/pharmaceutics15092294.
Promising Schiff bases in antiviral drug design and discovery.
Kaushik S, Paliwal S, Iyer M, Patil V Med Chem Res. 2023; 32(6):1063-1076.
PMID: 37305208 PMC: 10171175. DOI: 10.1007/s00044-023-03068-0.
Brudzynski K Metabolites. 2023; 13(4).
PMID: 37110183 PMC: 10141347. DOI: 10.3390/metabo13040526.